VCEL vs ZBH
VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee. ZBH: A global medical device company focused on musculoskeletal healthcare, including orthopedic implants and advanced surgical technologies.
Side-by-side fundamentals
| Metric | VCEL | ZBH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $40.05 | $88.88 | |
| Market cap | $2.1B | $17.0B | |
| P/E as of 2026-10-08 | 95.88 | 21.63 | ZBH lower |
| Net margin FY2025, SEC XBRL | +6.0% | +8.6% | ZBH higher |
| Gross margin FY2025, SEC XBRL | +74.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +4.0% | +13.3% | ZBH higher |
| ROE FY2025, SEC XBRL | +4.7% | +5.5% | ZBH higher |
| ROA FY2025, SEC XBRL | +3.4% | +3.1% | VCEL higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.59 | VCEL lower |
| Revenue growth (YoY) as of 2026-09-02 | +22.9% | +8.6% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | +18.9% | +5.9% | VCEL higher |
| Dividend yield as of 2026-09-02 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 15 | ZBH higher |
| Beta as of 2026-09-02 | 1.11 | 0.29 | |
| 1-year return as of 2026-10-08 close | +17.3% | -9.6% | VCEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.